Business context and reporting period
Entity discrepancy: The request identifies Crescent BioPharma, Inc., but the supplied filing is GlycoMimetics, Inc.’s Form 10-Q for the quarter ended June 30, 2014. This summary reflects the supplied filing.
GlycoMimetics is a clinical-stage biotechnology company with no commercialized products. Its lead candidate, rivipansel, is licensed worldwide to Pfizer; the company retains rights to its other candidates, including GMI-1271. Financial statements are unaudited.
Financial results and liquidity
| Metric | Q2 2014 / June 30, 2014 | Comparable period / prior balance |
|---|---|---|
| Revenue | $15.03 million | $55,000 in Q2 2013 |
| Operating expenses | $6.96 million | $3.55 million in Q2 2013 |
| Operating income (loss) | $8.06 million | $(3.50) million in Q2 2013 |
| Net income (loss) | $7.99 million; diluted EPS $0.39 | $(3.50) million; diluted EPS $(3.70) in Q2 2013 |
| Six-month revenue / net income (loss) | $15.03 million / $2.89 million | $3.86 million / $(3.04) million in first half 2013 |
| Cash from operating activities | $6.63 million for first half 2014 | $(6.58) million for first half 2013 |
| Cash and cash equivalents | $66.22 million | $2.31 million at December 31, 2013 |
| Total assets / total liabilities | $67.52 million / $3.64 million | $5.28 million / $2.38 million at December 31, 2013 |
Q2 operating margin was about 54%, but the filing’s revenue was almost entirely a one-time Pfizer milestone, so this is not a representative product margin. No debt balance is reported in the supplied financial statements. Accumulated deficit was $60.39 million.
Material changes versus prior period
- May 2014 Pfizer payment of $15.0 million drove Q2 and first-half revenue and the reported return to profit. In Q2 2013 revenue was only $55,000; first-half 2013 revenue mainly reflected recognition of deferred Pfizer upfront-payment revenue.
- Research and development expense rose 86% in Q2 to $5.36 million and 64% for the first half to $9.24 million, reflecting GMI-1271 development and manufacturing, its Phase 1 trial, and a $1.5 million University of Basel payment tied to the Pfizer milestone.
- General and administrative expense rose to $1.61 million in Q2 and $2.83 million for the first half, primarily due to IPO and public-company costs and higher stock compensation.
- Cash increased substantially following the January IPO, which generated $57.2 million net, and Pfizer’s milestone payment. First-half financing cash flow was $57.38 million.
Outlook, risks and unusual items
- Management expected June 30 cash to fund operations and capital spending for at least 12 months, excluding potential future Pfizer milestones. Management also expected significant expenses and operating losses over the coming years; profitability is uncertain.
- Pfizer planned to begin rivipansel Phase 3 enrollment in the second half of 2014; the filing says an FDA special protocol assessment had been agreed in July. The remaining $20 million of the scheduled Phase 3 milestone depended on first-patient dosing and other agreement conditions; timing and payment were not assured.
- GMI-1271’s Phase 1 study began in June 2014, with final data anticipated in the second half of 2014. A Phase 1/2 AML study was planned next. Timelines and clinical outcomes remain uncertain.
- Key risks include clinical-trial failure or delay, dependence on Pfizer for rivipansel development and potential milestone/royalty income, need for future financing, manufacturing and regulatory risks, and competition. The company had no product-sales revenue and may never become profitable.
- On July 23, 2014, the company signed a lease for future headquarters: eight years beginning November 1, 2015, with annual base rent of $607,500 subject to escalation. The existing Gaithersburg lease expires in October 2015. Total disclosed operating-lease obligations after the new lease were $5.97 million.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of June 30, 2014.
Important facts for investors to verify
- Confirm the filing identity: the supplied 10-Q is for GlycoMimetics, not Crescent BioPharma.
- Verify whether Pfizer initiated the Phase 3 trial, triggering the remaining $20 million milestone, and review any later updates to the SPA, trial timing, or agreement.
- Track GMI-1271 trial data, subsequent development plans, clinical costs, and availability of clinical drug supply.
- Assess cash runway against rising R&D and public-company costs; the stated 12-month runway was an estimate and excluded potential milestones.
- Distinguish recurring operating performance from the $15 million milestone that produced reported Q2 profit; also review dilution and share-based compensation.